Rifapentine

Drug Profile

Rifapentine

Alternative Names: DL 473; L 11473; M000473; MDL 473; Priftin; R 773

Latest Information Update: 18 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer Centers for Disease Control and Prevention; Sanofi; sanofi-aventis
  • Class Antituberculars; Rifamycins
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Tuberculosis
  • No development reported Mycobacterium avium complex infections

Most Recent Events

  • 18 Jul 2016 Biomarkers information updated
  • 18 May 2015 Withdrawn for Tuberculosis in Brazil (PO)
  • 02 Dec 2014 The US FDA approves rifapentine plus isoniazid for latent Tuberculosis infection in patients aged ≥2 years at risk of progression to Tuberculosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top